Furosemide VS Torasemide
Which is gentler on the kidneys, and more beneficial for elderly heart failure patients?
Does anyone have any information about this?
Which is gentler on the kidneys, and more beneficial for elderly heart failure patients?
Does anyone have any information about this?
dün 2 gün valörlü fon satış emri girmiştim. Bugün vazgeçtim, emri iptal etmenin bir yolu var mı? Emir iptaline basınca "ileri valorlu talimat iptal edilemez" diyor.
Are you over 80 and taking Lixiana (edoxaban) or Eliquis (apixaban), or do you know someone over 80 who has been prescribed either of these drugs?
Which medication provides greater protection for an atrial fibrillation patient over 80 years old?
Which one is more protective for 80+ elderly atrial fibrillation patiens?
ABSTRACT
Background: Based on efficacy and safety data from randomized controlled trials (RCTs) and real-world studies, direct oral anticoagulants are recommended for thromboembolism prevention in patients with atrial fibrillation (AF). However, no RCTs have compared edoxaban with apixaban. Objectives: This study aimed to retrospectively compare clinical outcomes for patients with AF in Italy (overall and by age group) who received edoxaban versus apixaban.
Conclusion: IS/SE risk was significantly lower for edoxaban versus apixaban, without an increased MB risk among patients with Atrial Fibrillation overall and those aged 80 years.
IS = ischaemic stroke, SE = systemic embolism, MB=major bleeding
Full length article:
https://doi.org/10.1055/a-2822-9746
https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-2822-9746.pdf
Background: The aim of the study was to compare the real-world effectiveness and safety in atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants (OACs) (apixaban, dabigatran, rivaroxaban, and vitamin K antagonists [VKA]) in Germany.
Conclusions: Edoxaban was associated with better effectiveness compared with other OACs in AF patients from Germany. Edoxaban also demonstrated a favorable safety profile.
Full length article: https://pubmed.ncbi.nlm.nih.gov/34780886/